La aspirina modifica en los megacariocitos las propiedades pre-apoptóticas de las plaquetas de novo

Zusammenfassung

Chronic treatment with low doses of acetylsalicylic acid (the term Aspirin or its abbreviation ASA will be used interchangeably throughout the text). Between 100-300 mg/day ASA doses, is used in the prevention of acute thrombotic vascular events. However, in a significant number of patients treated daily with ASA, their platelets are not completely inhibited. This effect is known as platelet resistance syndrome to ASA. Platelet ASA resistance syndrome is estimated to occur in 20% of the general population treated with ASA and up to 40% of the diabetic patient population. Different mechanisms involved in platelet resistance syndrome to ASA have been speculated, including non-adherence to treatment, prior administration of NSAIDs, the existence of a different isoform of cyclooxygenase, cyclooxygenase-2, in platelets, lack of ability of ASA-resistant platelets and / or leukocytes of patients with ASA-resistant platelets to generate nitric oxide etc...